“NHS access to these new drugs would not have made an appreciable difference to the experience of patients and families affected by dementia,” said Professor Rob Howard (UCL Psychiatry) on the NHS opting out of offering the new Alzheimer's drug donanemab.
Read: Mail Online
Close
